The fact that FTS can inhibit the growth of the AML cell line (which serves as an in vitro human model for LAM) and inhibits Rheb in these cells supports our suggestion that FTS should be considered as a possible treatment for LAM. Here, AKTIP is linked to lymphangioleiomyomatosis.